HRTX Heron Therapeutics, Inc.

14.30
-0.3  -2.05%
Previous Close 14.60
Open 14.50
Price To book 0.00
Market Cap N/A
Shares 0
Volume 704,062
Short Ratio 0.00
Av. Daily Volume 972,992

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released August 2016
HTX-011
Hernia repair
Phase 2 data released August 2016
HTX-011
Bunionectomy
CRL Mar 28 2013. Approved August 10 2016
APF530 - Sustol
Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV)
NDA filing announced January 12, 2017.
HTX-019
Prevention of chemotherapy-induced nausea and vomiting (CINV)

Latest News

  1. Acadia Pharmaceuticals Surge Higher Is More Than M&A Rumors
  2. Heron Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference
  3. LifeSci Capital Initiates Coverage of Heron Therapeutics
  4. Heron Therapeutics Announces Underwriters’ Exercise in Full of Option to Purchase Additional Shares
  5. HERON THERAPEUTICS, INC. /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi
  6. Heron Therapeutics Launches $150M Public Offering
  7. Heron Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
  8. Heron Therapeutics Announces Proposed Public Offering of Common Stock
  9. Heron Announces Submission of CINVANTI™ NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
  10. Heron Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
  11. Heron Therapeutics Inc Corporate Update Call scheduled for 8:30 am ET today
  12. Heron Therapeutics Establishes Synergy of Bupivacaine and Meloxicam with HTX-011 for Prevention of Post-Operative Pain in Phase 2 Clinical Studies
  13. Heron Therapeutics Announces Positive Topline Results From Phase 2 Clinical Trial of HTX-011 in Abdominoplasty
  14. HERON THERAPEUTICS, INC. /DE/ Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  15. Heron Therapeutics Establishes Synergy of Bupivacaine and Meloxicam with HTX-011 for Prevention of Post-Operative Pain in Phase 2 Clinical Studies
  16. Heron Therapeutics Announces Positive Topline Results From Phase 2 Clinical Trial of HTX-011 in Abdominoplasty
  17. What Smart Money Thinks about Echo Global Logistics, Inc. (ECHO)?
  18. Is Heron Therapeutics Inc (HRTX) a Good Stock To Buy?
  19. Susan G. Komen® Joins Forces With Heron Therapeutics to Raise Awareness of the Supportive Care Needs of Patients With Breast Cancer
  20. Heron Therapeutics, Inc. :HRTX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016